Application of the capsaicin 8% cutaneous patch in neuropathic pain of the head and face: A case series

Cephalalgia ◽  
2014 ◽  
Vol 35 (6) ◽  
pp. 545-550 ◽  
Author(s):  
Charly Gaul ◽  
Sonja Resch
Keyword(s):  
Neuropathic Pain ◽  
Facial Pain ◽  
Case Series ◽  
Additional Treatment ◽  
Line Treatment ◽  
First Line ◽  
Head Region ◽  
Affected Area ◽  
Pain Syndromes ◽  
First Line Treatment

Introduction Treatment of neuropathic or neuralgic head and facial pain due to dental, traumatic or surgical nerve lesions or post-herpetic neuropathy is often challenging. Cases We are reporting on four patients with neuropathic pain syndromes successfully treated with a capsaicin 8% patch in the affected area of the head or face. Discussion Treatment with the capsaicin 8% patch seems to be effective and safe for application to the facial and head region. The capsaicin 8% patch might be an additional treatment option if first-line treatment with anticonvulsants or antidepressants was ineffective or limited by side effects.

scholarly journals Pembrolizumab as first line treatment of Merkel cell carcinoma patients – a case series of patients with various co-morbidities

2020 ◽  
Vol 59 (7) ◽  
pp. 793-796 ◽  
Author(s):  
Tessa Bystrup Boyles ◽  
Mette Schødt ◽  
Helle Westergren Hendel ◽  
Anders Krarup-Hansen ◽  
Niels Junker
Keyword(s):  
Cell Carcinoma ◽  
Merkel Cell Carcinoma ◽  
Case Series ◽  
Line Treatment ◽  
Merkel Cell ◽  
First Line ◽  
First Line Treatment

Somatic Treatment of Catatonia

1995 ◽  
Vol 25 (4) ◽  
pp. 345-369 ◽  
Author(s):  
John M. Hawkins ◽  
Katharine J. Archer ◽  
Stephen M. Strakowski ◽  
Paul E. Keck
Keyword(s):  
Case Reports ◽  
Case Series ◽  
Complete Response ◽  
Positive Outcome ◽  
Line Treatment ◽  
First Line ◽  
Frequency Of Use ◽  
Specific Symptoms ◽  
First Line Treatment ◽  
Malignant Catatonia

Objective: The authors reviewed the recent literature regarding the treatment of catatonia as a syndrome of multiple etiologies. Given the historical and clinical association of catatonia with schizophrenia, the authors' examined the assumption that the first-line treatment of catatonia is antipsychotic medication. Methods: Articles published between January 1, 1985 and December 31, 1994 were located using the Paperchase® medical literature search system. Additionally, references from those identified articles were examined for possible inclusion in this review. To be included in this review, articles had to be written in English and report specific symptoms of catatonia to determine, retrospectively, if DSM-IV criteria for catatonia were met. Results: Seventy publications met inclusion criteria and reported on a total of 178 patients and included 270 separate treatment episodes. Most of the articles were case-reports, although a few case-series were identified. Multiple causes of catatonia were identified in these reports. The most commonly reported treatment for catatonia was with benzodiazepines which were effective in 70 percent of the cases, with lorazepam demonstrating the highest frequency of use and a 79 percent complete response rate. Electroconvulsive therapy (ECT) was also efficacious (85%) and was more likely to provide a positive outcome in cases of malignant catatonia. Antipsychotics demonstrated poor efficacy. Conclusions: Catatonia is a nonspecific syndrome with multiple etiologies. Treatment of catatonia should be based on the underlying cause when it is identifiable. Lorazepam appears to offer a safe, effective first-line treatment of catatonia. ECT should be considered when rapid resolution is necessary (e.g., malignant catatonia) or when an initial lorazepam trial fails.

The Use of Diphenylcyclopropenone in the Treatment of Recalcitrant Warts

2002 ◽  
Vol 6 (3) ◽  
pp. 214-217 ◽  
Author(s):  
Jennifer A. Upitis ◽  
Alfons Krol
Keyword(s):  
Side Effects ◽  
Response Rate ◽  
Dropout Rate ◽  
High Response Rate ◽  
Additional Treatment ◽  
Line Treatment ◽  
First Line ◽  
Effective Treatment Option ◽  
Topical Immunotherapy ◽  
First Line Treatment

Background: The treatment of recalcitrant palmoplantar and periungual warts using topical immunotherapy with diphenylcyclopropenone (DPC) was reviewed retrospectively over a seven-year period. Methods: Two hundred eleven patients were sensitized during this time. The patients consisted of 90 males and 121 females and were between 5 and 78 years old. Twenty-three patients were lost to followup. Of the remaining, 4 were undergoing treatment at the time of evaluation, 1 patient failed sensitization, and 1 patient became pregnant. Four discontinued because of side effects, 3 because of financial reasons, and 18 patients discontinued treatment prior to completing the minimum required applications (defined as 6), producing a dropout rate of 12% (25/211). Three patients had additional treatment during the course of DPC and were not included in the study. The remaining 154 patients were classified as nonresponders or responders. Results: The responders consisted of 135 individuals (87.7%) that had complete clearance of warts. Reported adverse effects were local and included with pruritus (15.6%), with blistering (7.1%), and with eczematous reactions (14.2%). The majority of the patients tolerated the treatment very well. One patient developed local impetigo. Patients had an average of 5 treatments over a 6-month period. Conclusions: Topical immunotherapy using DPC is an effective treatment option for recalcitrant warts. It should be considered as first-line treatment for warts based on its high response rate, absence of scarring, and painless application.

scholarly journals Left Renal Vein Stenting in Nutcracker Syndrome: Outcomes and Implications

2020 ◽  
Vol 3 ◽  
Author(s):  
Patrick Cherfan ◽  
Efthymios D Avgerinos ◽  
Rabih A Chaer
Keyword(s):  
Renal Vein ◽  
Left Renal Vein ◽  
Case Series ◽  
Flank Pain ◽  
Nutcracker Syndrome ◽  
Line Treatment ◽  
First Line ◽  
Extrinsic Compression ◽  
First Line Treatment

Nutcracker syndrome refers to the symptomatic extrinsic compression of the left renal vein presenting most commonly as flank pain and haematuria. While surgery remains the first-line treatment, stenting is gaining more acceptance and there are now several published case series. This article highlights the outcomes of left renal vein stenting in the setting of nutcracker syndrome.

scholarly journals Immunotherapy “Shock” a case series of PD-L1 100% and pembrolizumab first-line treatment

2017 ◽  
Vol 22 ◽  
pp. 197-202 ◽  
Author(s):  
Paul Zarogoulidis ◽  
Evaggelia Athanasiou ◽  
Theodora Tsiouda ◽  
Dimitrios Hatzibougias ◽  
Haidong Huang ◽  
...  
Keyword(s):  
Case Series ◽  
Line Treatment ◽  
First Line ◽  
First Line Treatment

Propranolol as First-Line Treatment in Orbital Infantile Haemangiomas: A Case Series

Orbit ◽  
2014 ◽  
Vol 33 (3) ◽  
pp. 178-183 ◽  
Author(s):  
M. Levitt ◽  
A. D. Coumou ◽  
L. Groeneveld ◽  
N. J. M. Freling ◽  
C. M. van der Horst ◽  
...  
Keyword(s):  
Case Series ◽  
Line Treatment ◽  
First Line ◽  
First Line Treatment ◽  
Infantile Haemangiomas

scholarly journals A Nine Case Series of Ultrasound-Guided Hydrostatic Reduction of Intussusception by Saline Enema

2013 ◽  
Vol 19 (1) ◽  
pp. 61-71
Author(s):  
Sornsupha Limchareon ◽  
Adisorn Boonyarit
Keyword(s):  
Case Series ◽  
Teaching Hospitals ◽  
Line Treatment ◽  
Ultrasound Guided ◽  
First Line ◽  
Hydrostatic Reduction ◽  
Pneumatic Reduction ◽  
Reduction Techniques ◽  
Enema Reduction ◽  
First Line Treatment

Non-surgical reduction of the intussusception is the first line treatment in children with intussusception. Among various radiological reduction techniques, barium enema reduction of the intussusception under fluoroscopy has been widely used in Thailand while pneumatic reduction under fluoroscopy has become popular in teaching hospitals. To our knowledge, ultrasound-guided hydrostatic reduction of the intussusception by saline enema (UGHSE) has never been used in Thailand. We reported 9 cases using UGHSE with 100% success rate without complication.

scholarly journals Endoscopic internal drainage as first-line treatment for fistula following gastrointestinal surgery: a case series

2016 ◽  
Vol 04 (06) ◽  
pp. E647-E651 ◽  
Author(s):  
Gianfranco Donatelli ◽  
Jean-Loup Dumont ◽  
Fabrizio Cereatti ◽  
Parag Dhumane ◽  
Thierry Tuszynski ◽  
...  
Keyword(s):  
Gastrointestinal Surgery ◽  
Case Series ◽  
Line Treatment ◽  
Internal Drainage ◽  
First Line ◽  
Endoscopic Internal Drainage ◽  
First Line Treatment

scholarly journals Targeted Combination Antibiotic Therapy Induces Remission in Treatment-Naïve Crohn’s Disease: A Case Series

2020 ◽  
Vol 8 (3) ◽  
pp. 371 ◽  
Author(s):  
Gaurav Agrawal ◽  
Annabel Clancy ◽  
Rijata Sharma ◽  
Roy Huynh ◽  
Sanjay Ramrakha ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Case Series ◽  
Line Treatment ◽  
First Line ◽  
Rapid Improvement ◽  
Line Therapy ◽  
Treatment Naïve ◽  
First Line Treatment

Prospective trials of anti-mycobacterial antibiotic therapy (AMAT) have proven efficacious in Crohn’s disease (CD) but use as first-line treatment in CD has not been evaluated. This paper reports the outcomes of patients with CD treated with first-line AMAT. This paper consists of a case series of treatment-naïve CD patients who received AMAT as first-line treatment between 2007 and 2014 at a single center. AMAT treatment consisted of rifabutin, clofazimine and clarithromycin, plus either ciprofloxacin, metronidazole or ethambutol. Symptoms, inflammatory blood markers, colonoscopy and histology results, in addition to, the Crohn’s Disease Activity Index (CDAI) were tabulated from patients’ clinical records, and descriptive statistics were conducted. A Wilcoxon signed-rank test assessed the difference in CDAI scores before and while on AMAT. The statistical significance was set at 5%. Clinical remission (CDAI < 150) with rapid improvement in clinical symptoms and inflammatory markers was seen in all eight patients receiving AMAT as sole therapy by 6 weeks. In all eight patients, the median CDAI score decreased significantly, from 289 prior to treatment to 62 at the 12-month follow-up (p < 0.001). Follow-up colonoscopies showed healing of CD ulcers, no visible mucosal inflammation, restoration of normal vascular patterns and complete mucosal healing on histology samples. AMAT as first-line therapy demonstrated a rapid improvement of Crohn’s disease (not previously seen when used as second-line therapy).

Sign in / Sign up

Export Citation Format

Share Document